Opioid Pharmacology

Correct Answer

A — Naturally occurring phenanthrene alkaloid and prototype full mu opioid receptor agonist

Rationale

Morphine is a naturally occurring alkaloid derived from the opium poppy and belongs to the phenanthrene chemical family. It is the prototype full mu opioid receptor agonist against which all other opioids are compared, producing maximum receptor activation and serving as the reference standard for equianalgesic dosing. A synthetic prodrug requiring hepatic conversion describes codeine, which depends on cytochrome P450 2D6 activity to produce morphine. A partial mu agonist with a ceiling effect on respiratory depression describes buprenorphine. A pure competitive antagonist with no intrinsic agonist activity describes naloxone.

Correct Answer

C — Pure competitive opioid antagonist at mu, kappa, and delta receptors with no intrinsic agonist activity

Rationale

Naloxone is a pure competitive opioid antagonist that binds with high affinity to mu, kappa, and delta receptors without activating them. It has no intrinsic agonist activity and produces no analgesia, sedation, or euphoria on its own. Its clinical utility derives entirely from its ability to competitively displace opioid agonists from receptors and reverse overdose. A full mu receptor agonist describes morphine. A partial mu agonist with kappa antagonist activity describes buprenorphine. A weak mu agonist combined with serotonin and norepinephrine reuptake inhibition describes tramadol.

Correct Answer

D — Partial mu receptor agonist and kappa receptor antagonist

Rationale

Buprenorphine is a semisynthetic opioid with a dual receptor profile: it is a partial agonist at mu receptors and an antagonist at kappa receptors. As a partial mu agonist, it activates the mu receptor but with submaximal efficacy, producing a ceiling effect on respiratory depression that makes it safer than full agonists in overdose. Its kappa antagonism contributes antidysphoric effects. Together these properties make buprenorphine valuable in both pain management and opioid use disorder treatment. A full mu agonist derived from the opium poppy describes morphine. A pure antagonist with no intrinsic activity describes naloxone. A prodrug requiring cytochrome P450 2D6 conversion describes codeine or tramadol.

Correct Answer

B — Synthetic phenylpiperidine full mu opioid receptor agonist with high lipophilicity and rapid onset

Rationale

Fentanyl belongs to the phenylpiperidine chemical family — a class of synthetic opioids that includes meperidine and the fentanyl congeners (sufentanil, alfentanil, remifentanil). It is a full mu opioid receptor agonist with approximately 100 times the potency of morphine. Its high lipophilicity allows rapid penetration of the blood-brain barrier, producing onset of action within one to two minutes of intravenous administration. Fentanyl is not a naturally occurring alkaloid and is not a prodrug. It is not a partial agonist and does not belong to the phenanthrene family (which includes morphine, codeine, and buprenorphine). It is not an antagonist and does not belong to the phenylheptylamines (which includes methadone).

Correct Answer

A — Naturally occurring phenanthrene opioid prodrug that requires hepatic conversion to morphine for its analgesic effect

Rationale

Codeine is a naturally occurring phenanthrene alkaloid derived from the opium poppy. It is classified as a prodrug because it has minimal intrinsic opioid receptor activity and depends on conversion to morphine by the cytochrome P450 2D6 enzyme in the liver to produce analgesia. This prodrug status is clinically important because cytochrome P450 2D6 genetic polymorphism makes codeine's analgesic effect highly variable: poor metabolizers obtain no analgesia, while ultrarapid metabolizers generate toxic morphine concentrations. A synthetic phenylpiperidine with high potency describes fentanyl. A partial mu agonist for opioid use disorder describes buprenorphine. A pure antagonist in the phenanthrene family describes naloxone or naltrexone.

Correct Answer

D — Weak mu opioid receptor agonist that also inhibits serotonin and norepinephrine reuptake

Rationale

Tramadol is classified as a dual-mechanism analgesic. Its opioid activity is relatively weak — it is a partial mu receptor agonist at standard doses — and its analgesic effect also depends on inhibition of serotonin and norepinephrine reuptake, which augments descending inhibitory pain pathways. This dual mechanism is associated with lower abuse potential than full mu agonists, though dependence and misuse do occur. The serotonergic component creates risk of serotonin syndrome when combined with monoamine oxidase inhibitors or selective serotonin reuptake inhibitors. A full mu agonist in the phenylpiperidine family describes fentanyl or meperidine. A pure antagonist for overdose reversal describes naloxone. A naturally occurring phenanthrene prodrug requiring cytochrome P450 2D6 conversion describes codeine.

Correct Answer

A — Inhibition of adenylyl cyclase, reducing intracellular cyclic adenosine monophosphate levels

Rationale

Activation of Gi and Go proteins inhibits adenylyl cyclase, reducing intracellular cyclic adenosine monophosphate levels. This decreases protein kinase A activity and downstream signaling in pain-processing neurons, contributing to opioid analgesia. With chronic opioid exposure, neurons compensate by upregulating adenylyl cyclase, which is the molecular basis of physical dependence — when opioids are removed, cyclic adenosine monophosphate surges above baseline and drives withdrawal symptoms. Gi/Go coupling activates inwardly rectifying potassium channels (causing hyperpolarization, not depolarization) and inhibits voltage-gated calcium channels (reducing neurotransmitter release, not increasing it) — the opposite of options C and D.

Correct Answer

D — Membrane hyperpolarization, reducing the likelihood of action potential firing

Rationale

Opening of inwardly rectifying potassium channels allows potassium ions to move out of the cell according to their electrochemical gradient, making the inside of the neuron more negative. This hyperpolarization moves the membrane potential away from the threshold for action potential firing, reducing neuronal excitability. In pain-processing neurons of the spinal cord dorsal horn and in brainstem respiratory centers, this hyperpolarization is a central mechanism of both opioid analgesia and respiratory depression. Depolarization would increase excitability — the opposite of the opioid effect. Increased calcium influx and increased glutamate release would enhance pain transmission rather than suppress it.

Correct Answer

B — Reduced calcium influx decreases release of pain-transmitting neurotransmitters from primary afferent terminals

Rationale

Calcium influx through voltage-gated calcium channels is required for neurotransmitter vesicle fusion and release at the presynaptic terminal. When opioids inhibit these channels on primary afferent pain fiber terminals in the spinal cord dorsal horn, the release of pain-transmitting substances — including glutamate, substance P, and calcitonin gene-related peptide — is reduced. This presynaptic inhibition of nociceptive synaptic transmission is a central mechanism of spinal opioid analgesia and explains why intrathecal opioids can produce profound analgesia at very low doses. Reduced calcium influx does not cause postsynaptic depolarization, does not increase cyclic adenosine monophosphate (Gi activation reduces it), and does not directly open potassium channels.

Correct Answer

C — Periaqueductal gray

Rationale

The periaqueductal gray is the most extensively studied and clinically important supraspinal opioid-sensitive structure. Mu receptor activation here triggers output neurons that project to brainstem structures including the rostral ventromedial medulla, which in turn activates descending noradrenergic and serotonergic pathways that suppress nociceptive transmission in the spinal cord dorsal horn. This descending inhibitory system is the mechanism underlying stress-induced analgesia and can be pharmacologically amplified by systemically administered opioids. The nucleus accumbens is the primary site of opioid-mediated euphoria and reward in mesolimbic circuits. The locus coeruleus is a noradrenergic nucleus involved in arousal and withdrawal states. The Edinger-Westphal nucleus mediates opioid-induced miosis through parasympathetic pupillary constriction.

Correct Answer

A — Opioid receptors are concentrated in the spinal cord dorsal horn where primary pain fibers synapse, allowing direct inhibition of pain transmission at low doses

Rationale

The spinal cord dorsal horn — particularly the superficial laminae that receive primary afferent pain fiber input — contains a high density of mu and delta opioid receptors on both presynaptic terminals and postsynaptic neurons. Intrathecal delivery places morphine directly at this site of action, allowing presynaptic calcium channel closure and postsynaptic potassium channel opening to inhibit pain transmission at doses 100 to 1,000 times lower than required systemically. Bypassing hepatic metabolism is relevant to oral versus intravenous comparisons, but does not explain intrathecal versus intravenous potency differences. Morphine is not converted to morphine-6-glucuronide in the intrathecal space. Intrathecal morphine does not preferentially activate periaqueductal gray pathways — its primary site of action at low doses is the dorsal horn itself.

Correct Answer

D — Constipation

Rationale

Tolerance — a reduced response at the same dose — develops to analgesia, euphoria, sedation, nausea, and respiratory depression with continued opioid exposure. Tolerance does not develop to constipation or to miosis. Constipation is mediated by mu receptors in peripheral enteric neurons that reduce gastrointestinal propulsive motility, and this effect persists throughout the course of chronic opioid therapy regardless of duration or dose. This is why prophylactic bowel regimens are standard of care for any patient starting regular opioid therapy, and why constipation remains a consistent complaint in long-term opioid users even when other initial adverse effects have diminished. Sedation, nausea, and euphoria all show at least partial tolerance development over days to weeks.

Correct Answer

B — Removal of opioid-mediated inhibition allows upregulated adenylyl cyclase to produce a surge of cyclic adenosine monophosphate above normal baseline levels

Rationale

With chronic opioid exposure, neurons adapt by upregulating adenylyl cyclase to compensate for persistent Gi/Go-mediated inhibition. When opioids are abruptly removed, the inhibitory input is lost, and the now-upregulated adenylyl cyclase operates unopposed, generating a surge of cyclic adenosine monophosphate far above normal levels. This rebound elevation drives the autonomic and somatic features of opioid withdrawal: anxiety, restlessness, sweating, piloerection, diarrhea, cramping, tachycardia, and hypertension. This is the molecular basis of physical dependence — it is a pharmacological neuroadaptation, not a behavioral disorder. Adenylyl cyclase upregulation does not directly desensitize opioid receptors, reduce receptor numbers, or affect potassium channel closure upon opioid removal.

Correct Answer

C — Mu receptor activation suppresses inhibitory interneurons in the ventral tegmental area, disinhibiting dopamine neurons and increasing dopamine release in the nucleus accumbens

Rationale

Dopamine neurons in the ventral tegmental area are normally held under tonic inhibitory control by gamma-aminobutyric acid-releasing interneurons. Mu receptor activation by opioids suppresses these inhibitory interneurons, removing their inhibitory influence on dopamine neurons — a process called disinhibition. The result is increased dopamine neuron firing and dopamine release in the nucleus accumbens, which produces the intense reward signal underlying opioid euphoria and reinforced drug-seeking behavior. Opioids do not directly stimulate the nucleus accumbens to release dopamine — the effect is indirect through disinhibition in the ventral tegmental area. Opioids do not increase dopamine synthesis in the ventral tegmental area, and they do not block dopamine reuptake transporters (that mechanism belongs to cocaine and amphetamines).

Correct Answer

A — Tolerance does not develop to the effects of morphine on peripheral mu receptors in enteric neurons

Rationale

Opioid-induced constipation is mediated by mu receptor activation in peripheral enteric neurons of the gastrointestinal tract, which reduces propulsive motility and prolongs intestinal transit. Unlike the central nervous system effects of opioids — analgesia, euphoria, sedation, nausea, and respiratory depression — tolerance does not develop to constipation with continued use. This patient's diminished analgesia and resolution of sedation reflect tolerance developing to the central nervous system effects, while the persistent constipation reflects the absence of tolerance at peripheral enteric mu receptors. Morphine does not accumulate in the gastrointestinal tract with chronic use. Constipation is mediated by mu receptors in the gut, not kappa receptors. Morphine-6-glucuronide accumulation is a concern in renal failure but does not cause selective gastrointestinal accumulation.

Correct Answer

D — Intrathecal morphine acts directly on the high density of mu receptors in the spinal cord dorsal horn, inhibiting pain transmission presynaptically and postsynaptically at the synapse where primary pain fibers enter

Rationale

The spinal cord dorsal horn contains a high density of mu and delta opioid receptors on both presynaptic terminals of primary afferent pain fibers and on postsynaptic dorsal horn neurons. Intrathecal delivery places morphine directly at this concentrated site of action. Presynaptically, opioids close voltage-gated calcium channels, reducing release of glutamate, substance P, and calcitonin gene-related peptide. Postsynaptically, opioids open potassium channels, hyperpolarizing dorsal horn neurons. Together these effects produce profound segmental analgesia at doses 100 to 1,000 times lower than systemic doses. Morphine is not converted to morphine-6-glucuronide in the intrathecal space. Intrathecal morphine does not preferentially activate periaqueductal gray pathways at low doses. First-pass metabolism affects oral versus intravenous differences, not intrathecal versus intravenous differences.

Correct Answer

B — Removal of opioid-mediated inhibition unmasks upregulated adenylyl cyclase, causing a surge of cyclic adenosine monophosphate that drives autonomic hyperactivity

Rationale

With chronic opioid exposure, neurons compensate for persistent Gi/Go-mediated inhibition of adenylyl cyclase by upregulating the enzyme. When opioids are abruptly removed, the inhibitory input is gone, and the now-hyperactive adenylyl cyclase generates a surge of cyclic adenosine monophosphate far above normal baseline. This rebound hyperactivity drives the autonomic and somatic features of opioid withdrawal: anxiety, restlessness, sweating, piloerection (gooseflesh), diarrhea, cramping, tachycardia, and hypertension. This is physical dependence — a pharmacological neuroadaptation that occurs predictably with regular opioid use and is distinct from addiction. Residual heroin metabolites would suppress rather than activate withdrawal. Mu receptor downregulation during chronic use is a component of tolerance but does not directly cause the autonomic features of withdrawal. Enkephalin depletion is not the established mechanism of opioid withdrawal.

Correct Answer

C — Rapid delivery of drug to the brain produces a faster and larger surge of dopamine release in the nucleus accumbens than the gradual rise from oral absorption

Rationale

The magnitude of opioid-induced euphoria correlates with the speed of drug delivery to the brain, not simply with the total amount of drug delivered. Intravenous injection produces rapid, high-peak concentrations in the brain, triggering an intense surge of dopamine release in the nucleus accumbens through disinhibition of dopamine neurons in the ventral tegmental area. Oral absorption produces a gradual, slower rise in brain drug levels and a correspondingly less intense dopamine surge and weaker euphoric effect. This pharmacokinetic rationale is why intravenous and intranasal routes carry substantially greater addiction risk than oral routes of the same drug, and it is the basis for abuse-deterrent extended-release opioid formulations designed to slow drug release. While bypassing first-pass metabolism does increase total bioavailability, this alone does not explain the intensity difference — speed of delivery is the critical variable. Intravenous administration does not selectively activate kappa receptors, and heroin metabolizes to morphine by both routes.